Regeneron Reports Positive Results in Colon Cancer Trial

Xconomy New York — 

Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi-aventis (NYSE: SNY) of France announced in a press release that their investigational drug aflibercept (Zaltrap) met its primary survival endpoint in a Phase III trial. The drug was tested as a second-line treatment in patients with colorectal cancer that had spread. “These findings are exciting given the limited second-line treatment options for patients with metastatic colorectal cancer,” George Yancopoulos, chief scientific officer of Regeneron and President of Regeneron Research Laboratories, said in the statement. The company plans to release details about the study at an upcoming medical meeting and to apply for FDA approval in the second half of the year.